您当前的位置:
SC75741
目录号: PC11561 纯度: ≥98%
CAS No. :913822-46-5
商品编号 规格 价格 会员价 是否有货 数量
PC11561-10mg 10mg ¥734.50 请登录
PC11561-50mg 50mg ¥7019.00 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
SC75741
中文别名
N-(6-苯甲酰基-1H-苯并咪唑-2-基)-2-(1-噻吩并[3,2-D]嘧啶-4-基-4-哌啶基)-4-噻唑甲酰胺;N-(6-苯甲酰基-1H-苯并咪唑-2-基)-2-(1-噻吩并[3,2-d]嘧啶-4-基-4-哌啶基)-4-噻唑羧酰胺
英文名称
SC75741
英文别名
4-Thiazolecarboxamide, N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)-;SC75741;N-(6-benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-yl-4-piperidinyl)-4-Thiazolecarboxamide;N-(6-benzoyl-1H-benzimidazol-2-yl)-2-[1-(2H-thieno[3,2-d]pyrimidin-1-yl)piperidin-4-yl]-1,3-thiazole-4-carboxamide;C29H23N7O2S2;HMS3653M06;BCP28754;2710AH;s7273;SB19538;AK685777;SW220215-1;A14278;N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)-2-(1-{thieno[3,2-d]pyrimidin-4-yl}piperidin-4-yl)-1,3-thiazole-4-carboxamide;N-(6-Benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno-[3,2-d];N-(6-Benzoyl-1H-benzimidazol-2-yl)-2-(1-thieno[3,2-d]pyrimidin-4-ylpiperidin-4-yl)-1,3-thiazole-4-ca
Cas No.
913822-46-5
分子式
C29N7O2S2H23
分子量
565.67
包装储存
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
生物活性

SC75741 is a broad and efficient NF-κB inhibitor with an IC50 of 200 nM for p65. SC75741 blocks influenza viruses (IV) replication. SC75741 impairs DNA binding of the NF-κB subunit p65, resulting in reduced expression of cytokines, chemokines, and pro-apoptotic factors. SC75741 subsequently inhibits caspase activation and blocks caspase-mediated nuclear export of viral ribonucleoproteins.

性状

Solid

IC50 & Target[1][2]

p65

200 nM (IC50)

体外研究(In Vitro)

SC75741 (5 μM; 24-96 hours) inhibits long-term A549 cells proliferation.
SC75741 (1-10 μM; 5.5-65 hours) reduces A549 cells viability in a concentration-dependent manner indicating a cytostatic effect for A549 cells within a time frame of about 50 and 65?hours.
SC75741 (5 μM; 24 hours) strongly inhibits cleavage of the effector caspase 3 induced upon H7N7-infection.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line: A549 cells
Concentration: 5?μM
Incubation Time: 24, 48, 72 and 96?hours
Result: Inhibited long-term cell proliferation

Cell Viability Assay

Cell Line: A549 cells
Concentration: 1, 2, 5 or 10?μM
Incubation Time: 5.5, 29, 50, 65 hours
Result: Reduced cells viability in a concentration-dependent manner.

Western Blot Analysis

Cell Line: MDCK cells
Concentration: 5?μM
Incubation Time: 24 hours
Result: Inhibited cleavage of the effector caspase 3 induced upon H7N7-infection.
体内研究(In Vivo)

SC75741 (intraperitoneal injection; 15?mg/kg; for 2 days) leads to a reduced propagation of the H5N1 virus mRNA by 90% in the lungs of infected mice.
The plasma-levels of SC74751 (intravenously of 5 mg/kg and intraperitoneally of 15 mg/kg; for 3.5 and 6 hours) after i.v. administration decreases mono-exponentially and half-life is roughly 40 min. After i.p. administration, elimination of SC75741 seems to be limited by a slow uptake from the peritoneum and a half-life of 55 min is observed.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Inbred female C57BL/6 mice at the age of 6-8 weeks
Dosage: 15?mg/kg
Administration: Intraperitoneal injection; for 2 days
Result: Reduced the amount of viral mRNA by 90%.
Animal Model: Inbred female C57BL/6 mice at the age of 6-8 weeks
Dosage: 5 mg/kg or 15 mg/kg
Administration: Intravenously of 5 mg/kg and intraperitoneally of 15 mg/kg; 3.5 and 6 hours
Result: Half-life was roughly 40 min and 55 min for i.v. and i.p. administration, respectively.
运输条件

Room temperature or refrigerated transportation.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献
溶解度数据
体外研究: 

DMSO : 83.33 mg/mL (147.31 mM; Need ultrasonic)

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7678 mL 8.8391 mL 17.6782 mL
5 mM 0.3536 mL 1.7678 mL 3.5356 mL
10 mM 0.1768 mL 0.8839 mL 1.7678 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    建议依照次序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (3.68 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.68 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH?O 中,得到澄清透明的生理盐水溶液
  • 2.

    建议依照次序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (3.68 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (3.68 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    建议依照次序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (3.68 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (3.68 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

相关产品

更多
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2